TriLink BioTechnologies Expands CleanCap® Intellectual Property Protection With New China Patent
TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, announced that it has received a new patent from the China National Intellectual Property Administration (CNIPA) covering its proprietary CleanCap® RNA capping technology.
The newly granted patent, China Patent No. ZL202511246658.5, is titled “Compositions and Methods for Synthesizing 5′-Capped RNAs.” The patent represents another expansion of TriLink’s intellectual property portfolio in China and marks the company’s second CleanCap® patent granted in the country within a relatively short period.
According to TriLink, the new patent is separate from and complementary to previously announced Chinese patent ZL202511246578.X, which focuses on methods for synthesizing capped RNA molecules. Together, the two patents provide protection across multiple aspects of the CleanCap® technology platform, encompassing both the processes used to produce capped RNA and the underlying cap analog compounds and resulting RNA-based compositions.
The expanded intellectual property position comes as mRNA and other RNA-based technologies continue to play an increasingly important role in biomedical research, vaccine development and therapeutic innovation.
New Chinese Patent Expands CleanCap® Protection
The latest CNIPA patent provides protection for several components associated with CleanCap® technology.
While the previously granted Chinese patent covers methods for synthesizing capped RNA molecules, the new patent addresses the CleanCap® cap analog compounds themselves. Its scope also extends to RNA molecules containing those compounds, cells containing such RNA molecules and pharmaceutical compositions, including drug products, incorporating CleanCap®-capped RNA.
This distinction is important from an intellectual property perspective because it creates protection at multiple levels of the technology.
One layer addresses how capped RNA can be manufactured using CleanCap® technology. Another protects the molecular compounds that enable the capping process, as well as RNA-containing compositions and pharmaceutical applications incorporating the resulting capped RNA.
The company describes the combined protection as a multi-layered intellectual property asset surrounding both the manufacturing process and fundamental molecular structures associated with CleanCap®.
Such protection can be particularly relevant in the rapidly developing RNA therapeutics field, where manufacturing technologies, molecular design and delivery systems are closely connected to the development and commercialization of RNA-based products.
Strengthening TriLink’s Presence in China
The latest patent also expands TriLink’s intellectual property position in one of the world’s major life sciences and pharmaceutical markets.
TriLink said its CleanCap® intellectual property portfolio extends across several strategically important markets, including the United States, European Union, Australia, Japan, Korea, Hong Kong, Canada and China.
The broader geographic reach is intended to provide intellectual property coverage as RNA-based research and product development programs advance internationally.
China has become an important market for biotechnology research, pharmaceutical development and advanced therapeutic platforms. Patent protection in the country can therefore play a role in supporting commercial activities involving proprietary technologies and enabling partnerships with organizations developing RNA-based medicines.
The new patent adds to TriLink’s existing intellectual property assets in China and further establishes the company’s position around CleanCap® technology.
CleanCap® as an RNA Manufacturing Technology
CleanCap® is designed to improve the process of adding protective 5′ caps to RNA molecules. RNA capping is a critical step in the development and manufacturing of many mRNA-based applications.
The 5′ cap structure can influence several important properties of an RNA molecule, including its stability, translation and interaction with cellular immune mechanisms. For therapeutic mRNA, these characteristics can affect how efficiently cells use the RNA to produce a desired protein.
TriLink says CleanCap® has demonstrated advantages in capping efficiency, translational performance and innate immune evasion. The company describes these attributes as key reasons the technology has become a widely used platform for researchers and developers working on RNA-based products.
The technology has applications across a range of research and development areas, including vaccines and therapeutic programs.
TriLink also states that its proprietary technology has been used in commercially approved COVID-19 mRNA and self-amplifying RNA (saRNA) vaccines, as well as in development programs spanning mRNA therapeutics, cancer vaccines, prophylactic vaccines, rare diseases and cell and gene therapies.
These applications illustrate the breadth of the RNA development ecosystem in which RNA capping technologies can play an enabling role.
Patent Protection Covers Multiple Stages of the Technology
The two Chinese patents provide complementary forms of intellectual property protection.
The earlier patent, ZL202511246578.X, focuses on methods for synthesizing capped RNA molecules. The newly granted ZL202511246658.5 adds protection for the compounds used in the capping technology, along with RNA molecules and pharmaceutical compositions containing those compounds.
Together, the patents provide a broader framework around CleanCap®.
Bernd Brust, Chief Executive Officer of Maravai LifeSciences, described the new patent as an important addition to the company’s CleanCap® intellectual property portfolio.
“This new Chinese patent represents an important expansion of our CleanCap® intellectual property position,” Brust said. “Where our first Chinese patent covers the methods of using CleanCap® to produce capped RNA, this new patent covers the cap analog compounds themselves and the pharmaceutical compositions that incorporate them.”
His comments highlight the complementary nature of the two patents. Rather than duplicating the earlier protection, the newly granted patent adds another layer around the technology and its potential applications.
Scientific Foundation Behind CleanCap®
TriLink’s intellectual property strategy is closely linked to the scientific development of its RNA capping platform.
Chanfeng Zhao, Chief Scientific Officer of TriLink BioTechnologies, emphasized the scientific work underlying the newly granted patent and the company’s continuing efforts to advance RNA capping technology.
“The granted claims in this patent reflect the deep scientific rigor our team applied in developing the CleanCap® platform,” Zhao said.
He added that TriLink remains focused on advancing the science of mRNA capping and said the company is proud that CleanCap® continues to be selected by researchers and developers working on important medicines.
RNA capping may appear to be one component of a broader RNA manufacturing workflow, but its characteristics can have significant downstream implications for therapeutic performance. As the industry develops increasingly sophisticated RNA medicines, technologies designed to optimize RNA structure and function remain important areas of research and commercial development.
Applications Across RNA-Based Medicine
TriLink’s CleanCap® technology is positioned for use across multiple segments of the biopharmaceutical industry.
One major application is mRNA therapeutics, where synthetic messenger RNA is designed to provide cells with instructions for producing specific proteins. Depending on the therapeutic strategy, such approaches may be investigated for protein replacement, immune modulation, genetic disease and other medical applications.
The technology also has applications in cancer vaccines, where RNA can be designed to encode tumor-associated or patient-specific targets intended to stimulate an immune response.
In prophylactic vaccines, mRNA and related RNA technologies have emerged as platforms capable of directing cells to produce antigens that train the immune system.
The company’s portfolio also supports research involving rare diseases and cell and gene therapies, demonstrating how RNA technologies can intersect with multiple areas of modern biomedical development.
The use of CleanCap® in commercially approved COVID-19 mRNA and saRNA vaccines further demonstrates the relevance of RNA capping technologies to products that have progressed beyond laboratory research into regulated commercial applications.
Intellectual Property and Commercial Licensing
In addition to supplying CleanCap® products, TriLink offers licensing opportunities for companies developing and commercializing mRNA-based products that incorporate its technology.
The company says organizations interested in using authentic CleanCap® materials can work directly with TriLink to establish a properly licensed supply chain.
Licensing can be an important consideration for companies developing commercial RNA products because intellectual property rights may cover specific molecular structures, manufacturing processes or applications. Establishing appropriate licensing arrangements can help companies address intellectual property considerations as programs progress through research, clinical development and commercialization.
For developers working on RNA-based products, access to qualified, high-quality reagents can also be an important component of manufacturing consistency and development planning.
TriLink’s licensing offering therefore complements its role as a supplier of life science reagents and services.
Expanding the RNA Technology Ecosystem
The new CNIPA patent arrives at a time when RNA technologies are being investigated across an increasingly diverse range of biomedical applications.
The success of mRNA vaccines has helped accelerate investment and research in RNA platforms, while advances in RNA chemistry, delivery systems and manufacturing are opening opportunities beyond infectious disease vaccination.
Technologies supporting RNA synthesis and modification are consequently becoming important components of the broader life sciences infrastructure.
Within this environment, TriLink’s CleanCap® platform is positioned as an enabling technology focused on the 5′ capping of RNA. The company’s expanding patent portfolio is intended to protect the scientific and technological foundation behind that platform across major global markets.
The Chinese patent adds another component to that international strategy by protecting not only the process of producing capped RNA but also the cap analog compounds and RNA-containing compositions associated with CleanCap®.
Broader Implications for mRNA Development
As pharmaceutical and biotechnology companies continue to explore RNA-based medicines, reliable manufacturing technologies are increasingly important to the development process.
RNA molecules must be produced with characteristics that support their intended biological function, and modifications such as 5′ capping can influence their behavior once introduced into biological systems. Advances in capping technologies therefore have implications for researchers seeking to improve RNA performance and develop new therapeutic approaches.
TriLink’s intellectual property strategy reflects this growing importance. By securing patent protection for both methods and compositions, the company is seeking to establish a broad foundation around CleanCap® technology.
The latest Chinese patent expands that foundation while complementing the previously announced patent covering synthesis methods.
Continued Investment in CleanCap® Technology
TriLink said it remains committed to advancing RNA capping science and supporting researchers and biopharmaceutical developers using RNA technologies.
The company’s CleanCap® portfolio now spans multiple major markets, while its commercial activities include reagent supply, life science services and licensing opportunities.
The newly granted CNIPA Patent No. ZL202511246658.5 adds further intellectual property protection in China and strengthens the overall portfolio surrounding CleanCap®.
For the broader RNA medicine industry, the development illustrates the growing importance of intellectual property surrounding enabling technologies—not only the final therapeutic products themselves. As RNA-based medicines expand into additional indications and therapeutic modalities, technologies that support their design, synthesis and manufacturing are likely to remain important components of the development ecosystem.
TriLink’s latest patent represents another step in protecting the company’s CleanCap® platform and the molecular technologies underlying its use in capped RNA. By combining protection for synthesis methods with protection for cap analog compounds, RNA molecules, cells and pharmaceutical compositions, TriLink is expanding the intellectual property framework supporting its RNA capping technology in China.
Companies seeking to incorporate CleanCap® technology into mRNA-based development and commercialization programs can engage with TriLink regarding available products, services and licensing opportunities. Further information is available through TriLink BioTechnologies.
About TriLink BioTechnologies
TriLink BioTechnologies, part of Maravai LifeSciences, is a global leader in nucleic acid technologies and manufacturing solutions for RNA therapeutics, vaccines, gene editing, and diagnostics. The company’s portfolio includes modified nucleotides, mRNA products, proprietary technologies such as CleanCap® capping analogs and ModTail® technology, and a growing portfolio of high-performance enzymes marketed under the Alphazyme brand. Supported by robust GMP manufacturing capabilities, TriLink enables customers from early-stage research through commercial production.
For more information, visit trilinkbiotech.com
About Maravai LifeSciences
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.